How does AmBisome compare with Abelcet® in terms of infusion-related reactions (IRR)?
In the empirical therapy study 97-0-034, on Day 1, where no premedication was administered, the overall incidence of infusion-related events of chills/rigors was significantly lower for patients administered AmBisome compared with amphotericin B lipid complex. Fever, chills/rigors and hypoxia were significantly lower for each AmBisome group compared with the amphotericin B lipid complex group. The infusion-related event hypoxia was reported for 11.5% of amphotericin B lipid complex-treated patients compared with 0% of patients administered 3 mg/kg per day AmBisome and 1.2% of patients treated with 5 mg/kg per day AmBisome.
Related Questions
- What are the most frequent adverse reactions associated with AmBisome therapy and how do they compare with those of amphotericin B deoxycholate?
- Is AmBisome associated with infusion-related reactions and how do they compare with those of amphotericin B deoxycholate?
- How does AmBisome compare with Abelcet in terms of nephrotoxicity?
